Trial Profile
A Multi-center, Open-label, Multiple Ascending Dosage-ranging Cohort (MAD) Study in Early, Untreated or Stably Treated Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetics (PK) of Injections of SER-214 Administered Subcutaneously Once a Week for Two Weeks After 0-2 Weeks of Dose Titration
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2023
Price :
$35
*
At a glance
- Drugs SER 214 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Serina Therapeutics
- 10 Apr 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 10 Apr 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.
- 21 Oct 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.